| A Study to Investigate the Effect of Food on Camlipixant Concentrations in Healthy Participants (NCT06497517) | Bellus Health Inc. - a GSK company | 2024-07-09 |
| A Study of Camlipixant in Male and Female Healthy Participants and Participants With Hepatic Impairment Aged 18-75 Years of Age (NCT06222892) | Bellus Health Inc. - a GSK company | 2024-02-02 |
| Evaluation of the Potential Drug-drug Interactions Between Gemfibrozil or Dabigatran Etexilate and Camlipixant (NCT05959447) | Bellus Health Inc. - a GSK company | 2023-07-26 |
| Evaluation of the Effect of Rifampin and Rabeprazole on the Pharmacokinetics of Camlipixant (NCT05899829) | Bellus Health Inc. - a GSK company | 2023-06-21 |
| A 24-Week Study of the Efficacy and Safety of BLU-5937 in Adults With Refractory Chronic Cough (NCT05600777) | Bellus Health Inc. - a GSK company | 2022-12-05 |
| A 52-Week Study of the Efficacy and Safety of BLU-5937 in Adults With Refractory Chronic Cough (NCT05599191) | Bellus Health Inc. - a GSK company | 2022-10-25 |
| Assessment of the Pharmacokinetics of BLU-5937 Extended Release Prototypes and a BLU-5937 Immediate Release Reference Formulation (NCT05570539) | Bellus Health Inc. - a GSK company | 2022-10-07 |
| Evaluation of the Pharmacokinetics and Safety of BLU-5937 in Healthy Adult Japanese and Caucasian Subjects (NCT06179537) | Bellus Health Inc. - a GSK company | 2021-08-06 |
| A Multiple-Dose Study of BLU-5937 in Chronic Pruritus Associated With Atopic Dermatitis (NCT04693195) | Bellus Health Inc. - a GSK company | 2020-12-09 |
| Evaluation of the Efficacy and Safety of BLU-5937 in Adults With Refractory Chronic Cough (NCT04678206) | Bellus Health Inc. - a GSK company | 2020-12-07 |
| Mass Balance Recovery, Absorption, Metabolism and Excretion of [14C]-BLU-5937 (NCT05244759) | Bellus Health Inc. - a GSK company | 2020-08-25 |
| A Dose Escalation Study of BLU-5937 in Unexplained or Refractory Chronic Cough (NCT03979638) | Bellus Health Inc. - a GSK company | 2019-07-10 |
| BLU-5937: First-in-Human, Single and Multiple Doses Escalation, Safety, Tolerability, Pharmacokinetics and Food Effect (NCT03638180) | Bellus Health Inc. - a GSK company | 2018-07-09 |
| A Phase IIa Proof-of-concept Study of NC-503 in Patients With Type II Diabetes (NCT00675857) | Bellus Health Inc. - a GSK company | 2008-04-01 |
| Open-Label Extension of the Phase III Study With Tramiprosate (3APS) in Patients With Mild to Moderate Alzheimer's Disease (NCT00314912) | Bellus Health Inc. - a GSK company | 2006-05-01 |
| European Study of 3APS in Mild to Moderate Alzheimer's Disease Patients (NCT00217763) | Bellus Health Inc. - a GSK company | 2005-09-01 |
| Evaluation of 3APS in Patients With Mild to Moderate Alzheimer's Disease (NCT00088673) | Bellus Health Inc. - a GSK company | 2004-06-01 |
| Cerebrilâ„¢ in Patients With Lobar Hemorrhage Related to Cerebral Amyloid Angiopathy (NCT00056238) | Bellus Health Inc. - a GSK company | 2003-02-01 |
| Study of the Safety and Efficacy of NC-503 in Secondary (AA) Amyloidosis (NCT00035334) | Bellus Health Inc. - a GSK company | 2001-10-01 |